Fundraising FoxThird Rock Ventures — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesNextech InvestPfizer Venture InvestmentsShangBay Capital LLCAgent Capital
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson Investors+4 more
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersEaston CapitalRA CapitalSanofi VenturesThink+ Ventures Management, LlcWakestream Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abata TherapeuticsAmbys Medicines
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.